Revance Therapeutics, Price on December 2, 2024
| RVNCDelisted Stock | USD 3.65 0.00 0.00% |
If you're considering investing in Revance Stock, it is important to understand the factors that can impact its price. As of today, the current price of Revance Therapeutics, stands at 3.65, as last reported on the 28th of March, with the highest price reaching 3.65 and the lowest price hitting 3.65 during the day. Revance Therapeutics, appears to be unstable, given 3 months investment horizon. Revance Therapeutics, maintains Sharpe Ratio (i.e., Efficiency) of 0.2, which implies the firm had a 0.2 % return per unit of risk over the last 3 months. By analyzing Revance Therapeutics,'s technical indicators, you can evaluate if the expected return of 0.71% is justified by implied risk. Please evaluate Revance Therapeutics,'s Variance of 42.72, coefficient of variation of (1,353), and Risk Adjusted Performance of (0.05) to confirm if our risk estimates are consistent with your expectations.
Revance Stock price history is provided at the adjusted basis, taking into account all of the recent filings.
Revance |
Sharpe Ratio = 0.2025
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | RVNC | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 3.51 actual daily | 31 69% of assets are more volatile |
Expected Return
| 0.71 actual daily | 14 86% of assets have higher returns |
Risk-Adjusted Return
| 0.2 actual daily | 15 85% of assets perform better |
Based on monthly moving average Revance Therapeutics, is performing at about 15% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Revance Therapeutics, by adding it to a well-diversified portfolio.
Related Headline
Akero Therapeutics Headline on 2nd of December 2024
Disposition of 10000 shares by Young Jonathan of Akero Thera... by Young Jonathan
Filed transaction by Akero Therapeutics Officer: Chief Operating Officer. Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
Revance Therapeutics, Valuation on December 2, 2024
It is possible to determine the worth of Revance Therapeutics, on a given historical date. On December 2, 2024 Revance was worth 3.61 at the beginning of the trading date compared to the closed value of 3.73. We use multiple weighted factors in our valuation methodologies to arrive at the intrinsic value of Revance Therapeutics, stock. Still, in general, we apply an absolute valuation method to find Revance Therapeutics,'s value based on its fundamental and technical indicators available within our service. As compared to an absolute model, our relative valuation model uses a comparative analysis of Revance Therapeutics, where we calculate exposure to its market risk and evaluate relevant financial multiples and ratios against Revance Therapeutics,'s related companies.
| Open | High | Low | Close | Volume | |
| 3.67 | 3.84 | 3.61 | 3.61 | 1,896,957 | |
12/02/2024 | 3.61 | 3.76 | 3.55 | 3.73 | 1,256,458 |
| 3.90 | 4.12 | 3.74 | 3.92 | 1,554,382 |
| Backtest Revance Therapeutics, | | | Revance Therapeutics, History | | | Revance Therapeutics, Valuation | Previous | Next |
Revance Therapeutics, Trading Date Momentum on December 2, 2024
| On December 03 2024 Revance Therapeutics, was traded for 3.92 at the closing time. The top price for the day was 4.12 and the lowest listed price was 3.74 . The trading volume for the day was 1.6 M. The trading history from December 3, 2024 was a factor to the next trading day price growth. The trading delta at closing time against the next closing price was 5.09% . The trading delta at closing time against the current closing price is 17.16% . |
Revance Therapeutics, Fundamentals Correlations and Trends
By evaluating Revance Therapeutics,'s financials over time, investors can gain insight into future company performance. However, you can also analyze the published financial statements to find patterns among Revance Therapeutics,'s main balance sheet or income statement drivers and many other relevant indicators that can statistically be found significantly correlated or uncorrelated. Revance financial account trend analysis is a perfect complement when working with valuation or volatility modules.About Revance Therapeutics, Stock history
Revance Therapeutics, investors dedicate a lot of time and effort to gaining insight into how a market's past behavior relates to its future. Access to timely market data for Revance is vital when making an investment decision, and regardless of whether you use fundamental or technical analysis, your return on investment in Revance Therapeutics, will depend on recognizing future opportunities and eliminating past mistakes. Historical data analysis is the study of market behavior over a given time. Recorded market-related data such as price, volatility, and volume can be quantified and studied over a defined period. Through a detailed examination of a market's past behavior, traders and investors can gain perspective on the inner workings of that market. The information obtained throughout analyzing Revance Therapeutics, stock prices may prove useful in developing a viable investing in Revance Therapeutics,
Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. Revance Therapeutics, Inc. was incorporated in 1999 and is headquartered in Nashville, Tennessee. Revance Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 495 people.
Revance Therapeutics, Stock Technical Analysis
Revance Therapeutics, technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, delisted stock market cycles, or different charting patterns.
Price Boundaries
Revance Therapeutics, Period Price Range
Low | March 28, 2025
| High |
0.00 | 0.00 |
Revance Therapeutics, cannot be verified against its exchange. Please verify the symbol is currently traded on NASDAQ Exchange. If you still believe the symbol you are trying to look up is valid, please let us know, and we will check it as soon as possible.
Revance Therapeutics, March 28, 2025 Market Strength
Market strength indicators help investors to evaluate how Revance Therapeutics, stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Revance Therapeutics, shares will generate the highest return on investment. By undertsting and applying Revance Therapeutics, stock market strength indicators, traders can identify Revance Therapeutics, entry and exit signals to maximize returns
Revance Therapeutics, Technical and Predictive Indicators
Predictive indicators are helping investors to find signals for Revance Therapeutics,'s price direction in advance. Along with the technical and fundamental analysis of Revance Stock historical price patterns, it is also worthwhile for investors to track various predictive indicators of Revance to make sure they correctly time the market and exploit it's hidden potentials. Even though most predictive indicators are useful for the short-term horizon, it's virtually impossible to predict the unforeseen market. For traders with a short-term horizon, predictive indicators add value when properly applied. Long-term investors, however, may find many predictive indicators less useful.
| Risk Adjusted Performance | (0.05) | |||
| Jensen Alpha | (0.49) | |||
| Total Risk Alpha | (0.29) | |||
| Treynor Ratio | (12.48) |
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. You can also try the Instant Ratings module to determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Other Consideration for investing in Revance Stock
If you are still planning to invest in Revance Therapeutics, check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Revance Therapeutics,'s history and understand the potential risks before investing.
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years |